

PARTNER WITH US

**REGISTER YOUR PLACE** 

## **Next Generation Cancer Vaccine Development** Summit

Unleashing Strong and Long-lasting Tumor-specific Responses

September 7-9 2021 | Digital Event

8am-5pm EST | 5am-2pm PST



**Optimize your** antigen selection combination therapy, and choice of platform to bring safe, personalized, and cost-effective cancer vaccines to market

Expert Speakers Include:



Karin Jooss Chief Scientific **Gritstone Oncology** 



Niranjan Sardesai Chief Executive Geneos Therapeutics



Alejandro Sepulveda Head of Cancer Janssen



Lena Kranz Director Cancer **BioNTech** 



Victor Levitsky Chief Scientific Officer Targovax



Laurent Humeau Chief Scientific Officer Inovio

🔇 (+1) 617 455 4188 info@hansonwade.com www.cancer-vaccine-development.com



WELCOME

## Powering mRNA, peptide, and other next-gen cancer vaccines to induce strong and long-lasting CD8+ responses

### Vaccines offer the promise of unleashing the most powerful force against cancer: our own immune system

With a better understanding of which antigens to target, advances in combination therapies, and recent approvals of newer vaccine platforms, the re-emergence of cancer vaccines has been met with promising clinical data, renewed investments, and unprecedented industry partnerships.

### The first Next Generation Cancer Vaccine Development Summit will

focus on overcoming the translational and clinical challenges of developing cancer vaccines, including finding the right antigens, reassessing patient populations, understanding immune suppression and resistance patterns, and exploring case studies covering **Ovarian Cancer, Pancreatic Cancer, Glioblastoma, Lung Cancer, Melanoma, Malignant pleural mesothelioma (MPM), Prostate Cancer, and Advanced Solid Tumors**.

With a focus on RNA, DNA, peptide, and other next-gen platforms, this niche 3-day agenda has specifically designed to equip industry with the necessary tools and knowledge to finally bring cost-effective cancer vaccines to market.

2

### Welcome to the inaugural Next Generation Cancer Vaccine Development Summit

🔵 gritstone

Understand how a novel primer boost vaccine using an adenoviral vector carrying srRNA can drive tumorspecific and potent CD8+ responses to guide your own internal choice of vaccine platform

Learn the critical steps in finding optimal antigens for cancer vaccinations, novel tumor bioavailability, and understanding transcriptional availability to accelerate preclinical development and reach the clinic with a robust product strategy

Janssen Johnson-Johnson

BIONTECH

Gain awareness of how mRNA platforms and individualized cancer immunotherapy targeting neoantigens identified on a patient by patient basis and selected for immunogenicity is revolutionizing the way we think about cancer therapy

Learn how DNA-based vaccine platforms can be used to treat a range of cancers and understand which key combination therapies can boost an specific, potent, and long-lasting T cell immune responses to accelerate your clinical trial design with immune checkpoint inhibitors





Understand the rationale of targeting unique antigens from individual patient tumors and gain awareness of abnormal mutations and suppression mechanisms to design, manufacture, and deliver personalized immunotherapies



### **Your Expert Speakers**



Nicholas Heimann **Chief Executive Officer** Nicholas **Pharmaceuticals** 



**Eric Halioua Chief Executive Officer PDC\*line Pharma** 



Niranjan Sardesai **Chief Executive Officer Geneos Therapeutics** 



**Tom Davis Chief Medical Officer Genocea Biosciences** 



Victor Levitsky **Chief Scientific Officer** Targovax

WELCOME

SPEAKERS

AGENDA

PARTNER WITH

SC



**Karin Jooss Chief Scientific Officer Gritstone Oncology** 



**Hanspeter Gerber** Chief Scientific Officer **3T Biosciences** 



**Jessica Flechtner** Chief Scientific Officer **Genocea Biosciences** 



Laurent Humeau Chief Scientific Officer Inovio

**Roman Yelensky** Chief Technology Officer **Gritstone Oncology** 



Wigard Kloosterman Chief Scientific Officer **Frame Therapeutics** 



**Peter Joyce** Chief Executive Officer **Grey Wolf** Therapeutics



Michael Ciesielski **Chief Executive Officer MimiVax** 



Agnete Fredriksen **Chief Scientific Officer** Vaccibody



**Alexandre Reuben** Assistant Professor The University off **Texas MD Anderson Cancer Center** 



**David Reardon** Clinical Director, Center for Neuro-Oncology **Dana-Faber Cancer** Institute



Eli Gilboa Director, Dodson Interdisciplinary Immunotherapy Institute University of Miami, **Miller School of Medicine** 



**Russell Pachynski** Assistant professor, Division of Oncology Washington **University School of** Medicine



**Mark Findeis** Executive Director, **Research Biochemistry Agenus Bio** 



**Ronit Satchi-Fainaro** Head, Cancer **Research and** Nanomedicine Laboratory **Tel Aviv University** 

Lelia Delamarre

Principal Scientist,

Cancer Immunology

Genentech



Alejandro Sepulveda Scientific Director, Head of Cancer Vaccines Janssen



**Hubert Lam Director Pre-clinical Genocea Biosciences** 



**Wouter Scheper** Senior Postdoctoral Fellow **Netherlands Cancer** Institute

**Helena Florindo** 

Group Leader, BioNanoSciences -

Drug Delivery and

Immunotherapy University of Lisbon



**Christopher Rose** Senior Scientist & Group Leader Genentech



Vipul Bhargava **Principal Scientist** Janssen



Lena Kranz **Director** Cancer Vaccines **BioNTech** 

An outstanding forum to gain valuable insights into new trends in cancer vaccine development Hanspeter Gerber, CSO, **3T Biosciences** 





# **Conference Day One** Tuesday, September 7

### 8.00-5.00 EST | 5.00 - 2.00 PST

		8.00 5.00	Virtual Coffee & Online Registration
		<b>8.45</b> 5.45	Chair's Opening Remarks
UNDERSTANDING THE TUMOR MICROENVIRONMENT & COMBINATION THERAPIES			MICROENVIRONMENT & COMBINATION THERAPIES
	Victor Levitsky Chief Scientific Officer Targovax	9.00 6.00	<ul> <li>Modulation Of The Tumor Micro-Environment By Oncos-102 - Experience From Several Types Of Cancer</li> <li>ONCOS-102 acts synergistically to reduce tumor volume with the chemotherapy combination of pemetrexed and cisplatin (Pem/Cis), which is the current standard of care in malignant pleural mesothelioma</li> <li>Demonstration that ONCOS-102 induces CD8+ T-cells specific to the tumor associated antigen (TAA) mesothelin, which is typically overexpressed in mesothelioma, as well as many other forms of cancer</li> </ul>
	Nicholas Heimann Chief Executive Officer Nicholas Pharmaceuticals	9.30 6.30	<ul> <li>Resurrecting and Supporting the Immune Response with Combination Therapy to Cure Pancreatic Ductal Adenocarcinoma</li> <li>Utilizing therapeutic interventions to create an internal vaccine.</li> <li>Rational utilization of PD-1 inhibitors in the treatment of PDAC.</li> <li>Complementing the immune response against cancer with EGFR/KRAS combination therapy.</li> </ul>
	David Reardon Clinical Director, Center for Neuro- Oncology Dana-Farber Cancer Institute	10.00 7.00	<ul> <li>Neoantigen Vaccination for Glioblastoma: Does Timing of Anti-PD-1 Matter?</li> <li>Better understand the rationale of combining neoantigen vaccination with anti-PD-1 therapy;</li> <li>Gain awareness of increasing preclinical data implicating how the timing of anti-PD-1 therapy may impact on anti-tumor immune responses generated by neoantigen vaccination;</li> <li>Appreciate the challenges of assessing the impact of anti-PD-1 timing</li> </ul>
		10.30 7.30	on anti-tumor immune responses generated by neoantigen vaccination in a prospective clinical trial. Morning Break & Speed Networking
	Alexandre Reuben Assistant Professor, Molecular Oncology The University of Texas MD Anderson Cancer Center	11.15 8.15	<ul> <li>Understanding Mechanisms Of Immune Resistance In Nsclc Through Analysis Of The T Cell Repertoire</li> <li>Substantial intratumor genomic and T cell heterogeneity (ITH) in early- stage NSCLC</li> <li>High frequency of bystander T cells are present in lung tumors</li> <li>Patients with more ITH and/or bystander T cells experience worse outcome</li> <li>Lung TILs recognize viral antigens</li> <li>Bystander TILs exhibit an unfavorable profile for anti-tumor responses</li> <li>Animal models allow the analysis of these phenomena and therapeutic strategies to overcome them</li> <li>Analysis of these mechanisms in patients treated with immunotherapy underway</li> </ul>
	Russell Pachynski Assistant Professor, Molecular Oncology Washington School of Medicine	11.45 8.45	<ul> <li>Altering the Human Prostate Tumor Immune Microenvironment Through Inhibition of Ibrutinib</li> <li>This is the first clinical trial of the BTK inhibitor ibrutinib in prostate cancer</li> <li>Ibrutinib may alter favorably alter the prostate tumor microenvironment by reducing pro-tumor B cells and increasing anti-tumor T cells</li> <li>Inhibition of BTK may also limit tumor cell-intrinsic growth</li> <li>Prostate tissue and peripheral correlative studies will be performed to evaluate the further use of ibrutinib in prostate cancer</li> </ul>

4

**REGISTER YOUR PLACE** 

# WELCOME

SPEAKERS

# **Conference Day One** Tuesday, September 7

12.45 9.45

### 8.00-5.00 EST | 5.00 - 2.00 PST



### CANCER VACCINE CASE STUDIES: mRNA, DNA, VIRAL VECTOR, PEPTIDE & DENDRITIC CELL

**Lunch Break & Virtual Networking** 

		<b>1.45 10.45</b>	A Novel Heterologous Prime Boost Vaccine System To Drive Tumor Specific T Cell Responses For Cancer Immunotherapy
Ø	Karin Jooss Chief Scientific Officer Gritstone Oncology		<ul> <li>Development of a potent heterologous prime/boost immunization approach to deliver predicted TSNAs to patients, which is comprised of a replication incompetent chimpanzee adenoviral vector (ChAdV) for the prime vaccination and a self-replicating, synthetic viral vector (srRNA) for repeated boost vaccinations</li> <li>Induction of high titer, polyfunctional and durable T-cell responses against non-self antigens</li> <li>Clinical trial updates will be highlighted</li> </ul>
A	Lélia Delamarre	<b>2.15 11.15</b>	Optimizing the Efficacy of mRNA-based Cancer Vaccines to
			Generate Potent and Long-lasting CD8+ Responses
	Principal Scientist,		Learning from preclinical models to guide and optimize mRNA-based     vaccine platforms
	Genentech		<ul> <li>Deciding the best combination therapy to use with mRNA</li> </ul>
			Determining anti-tumor T cell efficacy and future directions
		2.45 1.45	Targeting Unique Neoantigens From Individual Patient Tumors
			Optimized DNA plannid containing constant a containing constant in a containing constant in a containing conta
.96	Niranjan Sardesai		combination with IL-2 to boost T cell response
	Geneos		Electroporation-based delivery system for enhanced and efficient
			<ul> <li>plasmid uptake to allow optimal antigen production</li> <li>Combination therapy shows robust functional antigen specific CD4+ and CD8+ killer T cells</li> </ul>
		<b>3.15 12.15</b>	Afternoon Break & Speed Networking
		3.45 12.45	New class of Antigen-specific Cancer Active Immunotherapies based on an off-the-shelf Antigen Presenting Cell line
E	<b>Eric Halioua</b> Chief Executive Officer		<ul> <li>PDC*line is a new potent and scalable therapeutic cancer vaccines based on a proprietary allogeneic cell line of Plasmacytoid Dendritic Cells</li> <li>PDC*line is much more potent to prime and boost antitumor antigen.</li> </ul>
	PDC*line Pharma		including neoantigens, specific cytotoxic T-cells than conventional vaccines and improves the response to checkpoint inhibitors
			The technology can be applied for any cancer
		4.15 1.15	to Treat a Range of Cancers
P	Agnete Fredriksen Chief Scientific Officer Vaccibody		<ul> <li>Industry collaboration to generate individualized cancer treatments intended for use as a therapeutic vaccination in patient with locally advanced or metastatic tumors</li> <li>Clinical data to show a clear link between selection of high-quality neoepitopes and generation of strong neoepitope-specific CD8+ T cell</li> </ul>
		4 45 1 45	Chair's Closing Pomarks
		5 00 2 00	End of Day One
		5.00 2.00	

PARTNER WITH US

AGENDA

🕒 (+1) 617 455 4188 🛛 🞯 info@hansonwade.com

www.cancer-vaccine-development.com

5



# **Conference Day Two** Wednesday, September 8

### 8.00-5.00 EST | 5.00 - 2.00 PST

٢	8.00 5.00	Virtual Coffee & Online Registration
	8.45 5.45	Chair's Opening Remarks
OPTIMIZII	NG ANTIGEN	SELECTION, PRODUCTION, & PRESENTATION
Roman Yelensky Chief Technology Officer Gritstone Oncology	9.00 6.00	<ul> <li>Antigen Identification For Cancer Immunotherapy By Deep Learning On Tumor HIa Peptides</li> <li>Neoantigens are key tumor specific targets that may be targeted therapeutically</li> <li>Neoantigens can be identified for each patient using NGS and machine learning</li> <li>ctDNA can be used to evaluate neoantigen immunotherapies in the clinic</li> </ul>
	<mark>9.30</mark> 6.30	Identification of Novel pHLA Targets for Solid Tumor Targeting
Hans-Peter Gerber SVP and CSO 3T Biosciences		<ul> <li>Advantages of intracellular targets (pHLAs) versus viral, neoantigens or conventional cell surface antigens</li> <li>Strategies to find the most prevalent and immunogenic pHLA targets in tumors from CPI responders</li> <li>Selection of self-antigen targets with highest tumor vs normal ratios to avoid off-tumor, on-target toxicities</li> </ul>
	10.00 7.00	Personalized Cancer Vaccines: Technologies to Screen Neo-
Christopher Rose Senior Scientist & Group Leader Genentech		<ul> <li>Approaches to enhance presentation of epitopes from candidate neo- antigens</li> <li>A high throughput targeted mass spectrometry approach for sensitive detection neo-epitope presentation</li> <li>Looking toward next generation protein sequencing technologies for neo-epitope discovery</li> </ul>
	<b>10.30 7.30</b>	Morning Break & Speed Networking
Peter Joyce Chief Executiev Officer Grey Wolf	11.15 8.15	<ul> <li>ERAP1 Inhibition To Alter Tumor Visibility And Trigger Differentiated T Cell Responses</li> <li>Tumor visibility, defined as the level of tumor-specific antigen expression, is shown to strongly correlate with response to checkpoint inhibition and is a vital aspect determining the immunogenicity within the tumor microenvironment</li> <li>Grey Wolf have developed inhibitors of ERAP1, an aminopeptidase in the antigen presentation pathway that determines which antigens are</li> </ul>
merupeutics		<ul> <li>presented on the surface of a cell or tumor</li> <li>Grey Wolf ERAP1 inhibitors alter the immunopeptidome and thus visibility of the tumor, triggering a differentiated T cell response and causing tumor growth inhibition</li> </ul>

🛞 www.cancer-vaccine-development.com

6



# **Conference Day Two** Wednesday, September 8

8.00-5.00 EST | 5.00 - 2.00 PST

	11.45 8.45	Identification Of Patient-Specific T Cell Neoantigens Through Hla-Agnostic Genetic Screens	
Senior Postdoctoral		Identification of the T cell-recognized neoantigens in individual cancer     patients is complicated by their patient-specific nature.	
Netherlands Cancer		<ul> <li>We have developed the first genetic headhligen discovery platform that allows identification of both CD4+ and CD8+ T cell-recognized</li> </ul>	
Institute		neoantigens with high sensitivity and across complete HLA genotypes. <ul> <li>This technology should facilitate the development of personalized neoantigen-based cancer</li> </ul>	
	12.15 9.15	Whole Framome Cancer Vaccination Through Revolutionizing Neoantigen Detection	
Wigard Kloosterman Chief Scientific Officer Frame Therapeutics		<ul> <li>Frame Therapeutics focuses on a class of neoantigens, termed Frames, which represent long and completely foreign stretches of amino acids resulting from frame-shift mutations and genomic rearrangements in the tumor genome.</li> </ul>	
		• We show that our FramePro pipeline, combining a variety of sequencing technologies and bioinformatics analysis, can effectively identify all Frames expressed in cancer cells.	
	12.45 9.45	Lunch Break & Virtual Networking	
CANCER VACCINE C		SIMPNA DNA VIRALVECTOR & PEPTIDE CONTINUED	
	1.45 10.45	Rna-Encoded, Extended Half-Life Cytokines In Combination With Rna Vaccination For Synergistic Anti-Tumor Activity	
Lena Kranz		Optimized mRNA platform using lipid nanoparticle technology providing	
Director Cancer Vaccines BioNtech		<ul> <li>Proof of concept in an ongoing, first-in-human, dose-escalation phase I trial in patients with advanced melanoma (Lipo-MERIT) targeting non-</li> </ul>	
		<ul> <li>mutated, shared tumor-associated antigens</li> <li>Combination with RNA-encoded, extended half-life cytokines for T cell modulation and enhanced anti-tumor activity</li> </ul>	
	2 15 11 15	Leveraging Ontimized DNA Plasmid Design and Delivery to	
	2.13 11.13	Treat Glioblastoma Multiforme and Prostate Cancer	
Chief Scientific Officer		<ul> <li>Presentation of clinical trial data to show a DNA based cancer vaccine in combination with FLT3 ligand and PD-1 targeting metastatic castration</li> </ul>	
Inovio		<ul> <li>• Updates on clinical status of a GBM vaccine in combination with cemiplimab (PD-1 inhibitor)</li> </ul>	
Vipul Bhargava	2.45 11.45	lentification of shared Neoantigens in Prostate Cancer	
Principal Scientist Janssen			



7



WELCOME

**REGISTER YOUR PLACE** 

# **Conference Day Two** Wednesday, September 8

### 8.00-5.00 EST | 5.00 - 2.00 PST

	3.15 12.15	Afternoon Break & Speed Networking
Michael Ciesielski Assistant Professor, Neurosurgery & Oncology Roswell Park Cance Institute	3.45 12.45 *r	<ul> <li>Disrupting Glioblastoma: Survaxm Immunotherapy And Survivin Targeting Platforms</li> <li>SurVaxM is a novel cancer vaccine designed to stimulate an immune response targeting the tumor-specific antigen surviving</li> <li>A multi-center, single-arm phase 2a clinical trial of SurVaxM in survivin- positive newly diagnosed glioblastoma (nGBM, NCT02455557) is now complete</li> <li>Newly diagnosed glioblastoma patients were followed for safety, 6-month progression-free survival (PFS6), 12-month overall survival (OS12) and immunologic response</li> </ul>
		<ul> <li>SurVaxM immunotherapy generated encouraging efficacy and immunogenicity in nGBMand has minimal toxicity</li> <li>Trial design will be presented. Ongoing work with survivin and its tumor specific biology will be highlighted</li> </ul>
	4.15 1.15	Vaccination against shared neoantigens induced in recurrent and future tumors.
Eli Gilboa Director, Dodson Interdisciplinary Immunotherapy Institute University of Miami Miller School of Medicine		<ul> <li>=A common set of neoantigens are induced in disseminated tumor lesions by tumor targeted siRNA mediated inhibition of the peptide transporter TAP.</li> <li>=Vaccination against TAP downregulation induced neoantigens by targeted inhibition of TAP in resident dendritic cells Inhibited tumor growth in transplantable and autochthonous murine tumor models that was superior to vaccination against mutation-derived neoantigens, and was devoid of measurable toxicity.</li> <li>Vaccination against induced antigens using one or two broadly applicable chemically synthesized oligonucleotides will also benefit the majority of patients that do not express or express too few mutation- derived neoantigens.</li> </ul>
	<b>4.45 1.45</b>	Development of a First-in-class Shared Neo-Antigen Vaccine for the Treatment of Prostate Cancer
Alejandro Sepulveo Scientific Director, Head of Cancer Vaccines Janssen	la	<ul> <li>Data to show critical understanding of the tumor microenvironment to determine response to immune checkpoint therapy in combination with cancer vaccines</li> <li>Identification of VISTA as a potent inhibitory checkpoint that is predominantly expressed on CD68+ macrophages on PDACs, suggesting that VISTA may be a relevant immunotherapy target for effective treatment of patients with pancreatic cancer</li> </ul>
	5.15 2.15	Chair's Closing Remarks
	5.30 2.30	End of Day Two

Cancer Vaccines are a key step for the industry to overcome challenges in solid tumors. This summit is an important gathering of the minds to advance the next generation of life-saving therapies

8

SPEAKERS

SPEAKERS

# Post-Conference Workshop Day Thursday, September 9

### 11.00 - 1.00 EST | 8.00 - 10.00 PST

### **Workshop A**

### 10.00 - 12.00 EST | 7.00-9.00 PST

### **Exploring RNA-based Therapeutics to Better Understand Tumor Microenvironment, Drug Delivery, and Cancer Vaccine Development**

Session Objective: Attendees of this session will develop a greater understanding of how the tumor microenvironment can be modulated with RNA-based medicines based on previous cancer vaccine development work. Additionally, the workshop will cover a range of different cancers to draw comparisons between the key factors needed in vaccine development, appropriate combination therapies, and the effective role nanoparticle-based delivery plays in cancer immunotherapy.

### This workshop will discuss:

**Lunch Break** 

**Workshop B** 

- · RNAi delivery to regulate cancer and modulate its microenvironment.
- · Development of several peptide- and siRNA- based vaccines for melanoma
- · Development of Vaccines for glioblastoma, CRC, PDAC, and breast cancer
- Development of a novel nanoparticle-based therapeutic vaccine for breast cancer immunotherapy

### **Workshop Leader**



**Ronit Satchi-Fainaro** 

Head, Cancer Research and Nanomedicine Laboratory **Tel Aviv University** 



### **Helena Florindo**

1.00 - 2.00 EST | 10.00 - 11.00 PST

Group Leader, BioNanoSciences - Drug Delivery and Immunotherapy, **University of Lisbon** 

PARTNER WITH US

## <u>2.00 - 4.00 EST | 11.00 - 1.00 PST</u>

### Neoantigen selection to identify immunogenic tumor specific targets personalized to each patient's tumor and immune system

Session Objective: Attendees of this session will gain a greater understanding of personalized neoantigens relevant to both tumor and patient, and a uniquely identified immune suppressive class of proteins known as 'inhibigens' ™, which promote tumor growth and suppress immune anti-tumor effects. Additionally, the workshop will cover, from discovery to clinical trials, the development of a novel neoantigen vaccine, GEN-009, to treat a variety of tumors, optimized to the patient's own T-cells.

### This workshop will discuss:

- Individualized immune responses against infectious and malignant pathogens and their interaction with their host
- Neoantigens: Friend or Foe? Insights into tumor mutations and their ability
- GEN-009:a highly immunogenic Neoantigen Vaccine. Insights into Phase1/2A

### **Workshop Leaders**



**Tom Davis** Chief Executive Officer **Genocea Biosciences** 



**Hubert Lam** Director, Pre-clinical Development **Genocea Biosciences** 



9

# SPEAKERS

The Next Generation Cancer Vaccine Development Summit is committed to delivering the high-quality insights and industry connections that our customers expect, in a format that is accessible from the comfort of your home or office.

We have created this virtual summit to satisfy the industry's need to share cutting-edge research, learn from peers and engage in quality networking within a niche and highly selective audience to forge valuable collaborations.

To effectively facilitate this need to learn and connect, our custom-built virtual event platform will combine best-in-class platforms to deliver a seamless event experience. Accessing the platform is simple, you'll be provided with a unique link in the run up to the event that will take you directly to the online event space where you'll follow a few simple steps to set up your delegate profile and get started.

### **Key Features & Functionalities:**



### **Delegate Profile**

Set up personalized profiles to easily identify the name, job title & company of other attendees



### **Demo Area**

Visit the virtual exhibition area

to explore the solutions our specialist vendors have on offer

0	
$\hat{\mathbf{C}}$	Ļ
	2

### **Stage Area**

Most presentations will be delivered in the 'Stage' area, much like the main conference room onsite



### **Chat Rooms**

Connect with your peers and start conversations with individuals or all attendees in private and public chatrooms



### **Sessions Area**

Smaller groups can get together in this breakout

area for panel discussions and other interactive sessions



### **Speed Networking**

This virtual networking session will connect

you with other attendees to establish new industry contacts

# AGENDA

PARTNER WITH US

### What You Can Expect from a Digital Event:



### Live Q&As with **Speakers**

10

Ask your burning questions directly to our expert speakers in real-time, just as you would at a physical conference



### **Audience Discussions**

Join smaller, informal group chats or video calls designed to spark crucial conversations around key challenges for the industry



7+ Hours of Networking

Facilitated and informal networking breaks will allow you to connect 1-2-1 with other attendees and kick start critical discussions



### **Content Available Post-Event**

On conclusion of the event, presentations will be made available to attendees where possible

**REGISTER YOUR PLACE** 

If you have any other questions about the platform, please get in touch

🖲 (+1) 617 455 4188 🛛 🙆 info@hansonwade.com www.cancer-vaccine-development.com



# WELCOME

# **Partner With Us**

Partnering with Next Generation Cancer Vaccine Summit is your opportunity to demonstrate your expertise, elevate your brand, and establish yourself as a key thought leader and front runner within the immune-oncology community.

### Your brand, your message, and your reputation showcased in front of translational and clinical experts from the field of cancer vaccine development.

With a huge amount of excitement and innovation within the immune-oncology space at the moment, and an ever-

increasing number of companies launching new cancer vaccine candidates into preclinical and clinical studies, there is a unique opportunity for pre-clinical CROs, adjuvant formulators, peptide providers, and immune reagent suppliers to establish themselves as the go-to commercial partners for the industry.

We will work with you to build bespoke partnerships to ensure you meet your 2021 business objectives. Get in touch today to learn more about how we can support you and your commercial goals within the vaccine development field.

• A truly outstanding summit that provides a unique opportunity for cross-functional information and experience sharing, thereby showing the way forward in immune oncology development **P** 

### Peggy Sotiropoulou, Head of R&D, Celyad Oncology



# **GET INVOLVED**

11



**Jack Marcus** Partnerships Director Tel: (+1) 6174554188 Email: sponsor@hansonwade.com



hansonwade

**REGISTER YOUR PLACE** 

## **Ready to Register?**

### 3 Easy Ways To Book



www.cancer-vaccine-development.com/ take-part/register

Tel: (+1) 617 455 4188

Email: register@hansonwade.com



**Progress** your own expertise and experience while forging complementary partnerships and alliances

**Overcome** immunogenicity challenges and design safe and efficacious vaccine formulations

**Define** clinically meaningful endpoints to successfully develop and safely deliver optimal doses for public use

Drug Developer	Register and Pay by Friday May 14	Standard Pricing
Conference + Workshop Day	\$1,897 <b>(Save \$800)</b>	\$2,697
Conference Only	\$1,499 <b>(Save \$500)</b>	\$1,999
Academic & NPO	Register and Pay by Friday May 14	Standard Pricing
Conference + Workshop Day	\$1,497 <b>(Save \$900)</b>	\$2,397
Conference Only	\$1,199 <b>(Save \$600)</b>	\$1,799
Service Provider	Register and Pay by Friday May 14	Standard Pricing
Conference + Workshop Day	\$2,497 <b>(Save \$800)</b>	\$3,297
Conference Only	\$1,899 <b>(Save \$600)</b>	\$2,499

Please visit the website for full pricing options or email info@hansonwade.com

All prices shown in USD. If you are a UK or EU-based company, you may be subject to 20% VAT in addition to the price advertised. If you qualify for a reverse charge, you will have the option to provide your VAT number and the charge will be automatically deducted at checkout.

Gain great insights into new trends and mix with the thought leaders in cancer vaccine development

### Genentech

### **Team Discounts\***

- 10% discount 3 Attendees
- 15% discount 4 Attendees
- 20% discount 5 or more Attendees

\*Please note that discounts are only valid when three or more delegates from one company book and pay at the same time.

Discounts cannot be used in conjunction with any other offer or discount. Only one discount offer may be applied to the current pricing rate.

Contact: register@hansonwade.com

### TERMS & CONDITIONS

12

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancellations received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Every reasonable effort will be made to adhere to the event programme as advertised. However, it may be necessary to alter the advertised content, speakers, date, timing, format and/or location of the event. We reserve the right to amend or cancel any event at any time. Hanson Wade is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disaters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your industry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please write to: Database Manager, Hanson Wade, Suite A, 6 Honduras Street, London ECTY OTH

